Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Net Income (2016 - 2025)

Historic Net Income for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $540000.0.

  • Akebia Therapeutics' Net Income rose 10269.47% to $540000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 6541.79%. This contributed to the annual value of -$69.4 million for FY2024, which is 3367.36% down from last year.
  • Per Akebia Therapeutics' latest filing, its Net Income stood at $540000.0 for Q3 2025, which was up 10269.47% from $247000.0 recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Net Income registered a high of $29.0 million during Q2 2022, and its lowest value of -$84.3 million during Q2 2021.
  • In the last 5 years, Akebia Therapeutics' Net Income had a median value of -$18.0 million in 2024 and averaged -$26.1 million.
  • Its Net Income has fluctuated over the past 5 years, first skyrocketed by 13444.48% in 2022, then plummeted by 381400.65% in 2024.
  • Akebia Therapeutics' Net Income (Quarter) stood at -$70.4 million in 2021, then surged by 90.76% to -$6.5 million in 2022, then surged by 109.44% to $614000.0 in 2023, then crashed by 3814.01% to -$22.8 million in 2024, then skyrocketed by 102.37% to $540000.0 in 2025.
  • Its Net Income stands at $540000.0 for Q3 2025, versus $247000.0 for Q2 2025 and $6.1 million for Q1 2025.